---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-016562"
form_type: "8-K"
ticker: "RMSL"
cik: "0001412126"
company_name: "RemSleep Holdings Inc."
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T11:50:47.839619+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# RemSleep reports cytotoxicity test failures on DeltaWave cannula; new lab to retest

## Summary
- Two cytotoxicity tests on DeltaWave cannula MD, Angled Adaptor and Flexible Hose failed in early 2022.
- Superior Toxicology & Wellness concluded original testing protocols were flawed and erroneous.
- New third-party lab will conduct cytotoxicity tests with corrected procedures.
- Initial tests by Product Safety Labs in New Jersey; both were failures.
- CEO Tom Wood received letter from Dr. Joe Nieusma on March 25, 2022.

## SEC filing metadata
- accession: 0001213900-22-016562
- form_type: 8-K
- ticker: RMSL
- cik: 0001412126
- company_name: RemSleep Holdings Inc.
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412126/000121390022016562/0001213900-22-016562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412126/000121390022016562/ea157712-8k_remsleep.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-016562
- JSON: https://secwatch.observer/filing/0001213900-22-016562.json
- Plain text: https://secwatch.observer/filing/0001213900-22-016562.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.